---
title: "Profusa (PFSA) news: convertible notes and merger"
url: "https://aibio.space/companies/profusa/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "PFSA convertible notes and merger news: Profusa issues $769,230.77 secured convertible note to Ascent Partners. Profusa, Inc. (NASDAQ: PFSA), United States."
---

PFSA Profusa, Inc. NASDAQ · United States

# Profusa (PFSA) news PFSA convertible notes and merger news

Debt Financing · 2026-10-15

## [Profusa issues $769,230.77 secured convertible note to Ascent Partners](https://aibio.space/news/profusa-issues-769-230-77-secured-convertible-note-ascent-partners/)

The note carries 7% interest, converts at $4.28 a share and matures in October 2027.

## Latest Profusa news

1. 2026-10-04 Debt Financing [Profusa amends Ascent Partners convertible note terms](https://aibio.space/news/profusa-amends-ascent-partners-convertible-note-terms/) Ascent Partners Fund LLC is the holder and collateral agent. The exhibit sets a $0.338 floor, a 150% share reserve and waivers on three later notes, and Profusa had $719,000 in cash and cash equivalents at June 30, 2026.
2. 2026-09-16 Debt Financing [Profusa sells senior secured convertible note to Ascent Partners Fund](https://aibio.space/news/profusa-sells-senior-secured-convertible-note-ascent-partners-fund/) Ascent Partners Fund LLC bought the note as initial purchaser and also acts as collateral agent. The $384,615.38 note was sold for $350,000, and Profusa had $719,000 in cash and cash equivalents at June 30, 2026.
3. 2026-09-01 Debt Financing [Profusa sells another senior secured convertible note to Ascent](https://aibio.space/news/profusa-sells-another-senior-secured-convertible-note-ascent/) The note has a principal amount of $329,670.33 and was sold for $300,000.00, reflecting original issue discount. Ascent Partners Fund LLC is the initial purchaser.
4. 2026-08-20 Listings [Profusa reports Q2 2026 results and progress on G3 option](https://aibio.space/news/profusa-reports-q2-2026-results-progress-g3-option/) Profusa reported cash of $719,000 at June 30, 2026, and said it expects stockholders' equity of $28.4 million as of July 31, 2026.
5. 2026-08-12 Debt Financing [Profusa issues $714,285.72 senior secured convertible note](https://aibio.space/news/profusa-issues-714-285-72-senior-secured-convertible-note/) The note has a $650,000.00 purchase price and matures in August 2027. The filing names no placement agent or advisor.
6. 2026-07-27 Debt Financing [Profusa expects about $7 million convertible note alongside diagnostics deal](https://aibio.space/news/profusa-expects-about-7-million-convertible-note-alongside-diagnostics/) Profusa signed a non-binding term sheet to acquire a private diagnostics company that it says had about $111 million of 2025 revenue. The deal would come with an estimated $7 million convertible note at a 7% rate and a 9% original issue discount.

## Profusa at a glance

- **Ticker**: PFSA

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $719,000

### Related companies

- [UL Solutions](https://aibio.space/companies/ul-solutions/) NYSE: ULS
- [LAKELAND INDUSTRIES INC](https://aibio.space/companies/lakeland-industries/) NASDAQ: LAKE
- [Ascend Wellness Holdings](https://aibio.space/companies/ascend-wellness/) OTC: AAWH
- [Anteris Technologies Global](https://aibio.space/companies/anteris-technologies-global/) NASDAQ: AVR
- [PyroGenesis Canada](https://aibio.space/companies/pyrogenesis-canada/) OTC: PYRGF
- [TRINITY BIOTECH](https://aibio.space/companies/trinity-biotech/) NASDAQ: TRIB
- [ESCALON MEDICAL CORP](https://aibio.space/companies/escalon-medical/) OTC: ESMC
- [Picard Medical](https://aibio.space/companies/picard-medical/) NYSE: PMI

### Also on NASDAQ

- [Agenus](https://aibio.space/companies/agenus/) AGEN
- [Vertex Pharmaceuticals](https://aibio.space/companies/vertex-pharmaceuticals/) VRTX
- [Moleculin Biotech](https://aibio.space/companies/moleculin-biotech/) MBRX
- [SI-BONE](https://aibio.space/companies/si-bone/) SIBN
- [Absci](https://aibio.space/companies/absci/) ABSI
- [Spero Therapeutics](https://aibio.space/companies/spero-therapeutics/) SPRO

## Profusa annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue |  | [$100,000](https://www.sec.gov/Archives/edgar/data/1859807/000121390026044046/) |
| Research and development | [$2.8 million](https://www.sec.gov/Archives/edgar/data/1859807/000121390026044046/) | [$1.6 million](https://www.sec.gov/Archives/edgar/data/1859807/000121390026044046/) |
| Net income (loss) | [-$35.8 million](https://www.sec.gov/Archives/edgar/data/1859807/000121390026044046/) | [-$9.2 million](https://www.sec.gov/Archives/edgar/data/1859807/000121390026044046/) |
| Cash from operations | [-$16.2 million](https://www.sec.gov/Archives/edgar/data/1859807/000121390026044046/) | [-$2.1 million](https://www.sec.gov/Archives/edgar/data/1859807/000121390026044046/) |
| Cash and equivalents | [$1.8 million](https://www.sec.gov/Archives/edgar/data/1859807/000121390026057887/) | [$191,000](https://www.sec.gov/Archives/edgar/data/1859807/000121390026044046/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $719,000.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Profusa

Has Profusa sold convertible notes?

Our latest story on this, dated Oct 15, 2026: "Profusa issues $769,230.77 secured convertible note to Ascent Partners". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/profusa-issues-769-230-77-secured-convertible-note-ascent-partners/).

Is Profusa involved in a merger or acquisition?

Our latest story on this, dated Jul 27, 2026: "Profusa expects about $7 million convertible note alongside diagnostics deal". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/profusa-expects-about-7-million-convertible-note-alongside-diagnostics/).

What is the ticker symbol of Profusa?

Profusa, Inc. trades under the ticker PFSA on NASDAQ.

Where is Profusa listed?

Profusa, Inc. is listed on NASDAQ.

Which country or territory is Profusa listed under?

Our directory records Profusa, Inc. under United States.

Does aibio.space cover Profusa?

aibio.space lists Profusa, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Is Profusa profitable?

Profusa, Inc. reported a net loss of $35.8 million for the fiscal year ended Dec 31, 2025, and used $16.2 million of cash in operations, per its annual report to the SEC.

How much does Profusa spend on research and development?

$2.8 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does Profusa have?

$719,000 in cash at Jun 30, 2026, per its 10-Q.

What is the latest Profusa (PFSA) stock news?

Our latest story on Profusa, dated Oct 15, 2026: "Profusa issues $769,230.77 secured convertible note to Ascent Partners". The note carries 7% interest, converts at $4.28 a share and matures in October 2027. [Source](https://aibio.space/news/profusa-issues-769-230-77-secured-convertible-note-ascent-partners/).

Is Profusa at risk of delisting?

Our latest listing story, dated Aug 20, 2026: "Profusa reports Q2 2026 results and progress on G3 option". Profusa reported cash of $719,000 at June 30, 2026, and said it expects stockholders' equity of $28.4 million as of July 31, 2026. [Source](https://aibio.space/news/profusa-reports-q2-2026-results-progress-g3-option/).

How can I follow Profusa (PFSA) news?

Press Follow on this page to add Profusa to your Following list, or subscribe to the aibio.space newsletter. We have published 7 stories naming Profusa so far, in Debt Financing, Listings.

## Investor discussion: Profusa

Members talk about Profusa (PFSA). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Profusa, newest first. Each line links the filing it comes from.

1. 2026-10-09 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1859807/000121390026108552/ea0308134-8k_profusa.htm)
2. 2026-09-21 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1859807/000121390026101568/ea0306040-8k_profusa.htm)
3. 2026-09-15 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1859807/000121390026099871/ea030512101ex99-1.htm)
4. 2026-08-31 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1859807/000121390026095405/ea030394501ex99-1.htm)
5. 2026-08-28 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1859807/000121390026095087/ea0302274-02.htm)
6. 2026-08-18 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1859807/000121390026091323/ea0302274-01.htm)
7. 2026-08-14 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1859807/000121390026089362/ea030148402-8kex99i_profusa.htm)
8. 2026-08-14 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1859807/000121390026090082/ea0302271-nt10q_profusa.htm)
9. 2026-07-31 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.03,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1859807/000121390026084064/ea030001701ex99-1.htm)
10. 2026-07-06 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1859807/000121390026075502/ea029713001ex99-1.htm)
11. 2026-06-23 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1859807/000121390026070970/ea0295656-8k_profusa.htm)
12. 2026-05-26 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1859807/000121390026060916/ea0289795-02.htm)
13. 2026-05-15 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1859807/000121390026057182/ea029102301ex99-1.htm)
14. 2026-05-12 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1859807/000121390026055064/ea0289795-01.htm)
15. 2026-05-08 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1859807/000121390026053535/ea028959701ex99-1.htm)
16. 2026-04-29 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,2.03,3.01,3.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1859807/000121390026049432/ea0288135-8k_profusa.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:PFSA on TradingView](https://www.tradingview.com/symbols/NASDAQ-PFSA/).

## Listing details

Profusa, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker PFSA, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Profusa, Inc.

- **Ticker**: PFSA

- **Listing**: NASDAQ

- **Country or territory**: United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/profusa/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Profusa (PFSA) news: convertible notes and merger", 2026-10-31, https://aibio.space/companies/profusa/